发布求助
文献互助 智能选刊 最新文献

Thrombosis最新文献

筛选
英文 中文
Clinical use of aspirin in treatment and prevention of cardiovascular disease. 阿司匹林在治疗和预防心血管疾病中的临床应用。
Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-24 DOI: 10.1155/2012/245037
Yuxiang Dai, Junbo Ge
{"title":"Clinical use of aspirin in treatment and prevention of cardiovascular disease.","authors":"Yuxiang Dai,&nbsp;Junbo Ge","doi":"10.1155/2012/245037","DOIUrl":"https://doi.org/10.1155/2012/245037","url":null,"abstract":"<p><p>Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"245037"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/245037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30346871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 71
Experimental Validation of Methods for Prophylaxis against Deep Venous Thrombosis: A Review and Proposal. 深静脉血栓预防方法的实验验证：回顾与建议
Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-04-10 DOI: 10.1155/2012/156397
Paul S Agutter, P Colm Malone, Ian A Silver
{"title":"Experimental Validation of Methods for Prophylaxis against Deep Venous Thrombosis: A Review and Proposal.","authors":"Paul S Agutter, P Colm Malone, Ian A Silver","doi":"10.1155/2012/156397","DOIUrl":"10.1155/2012/156397","url":null,"abstract":"<p><p>The experimental procedure by which the valve cusp hypoxia (VCH) hypothesis of the etiology of deep venous thrombosis (DVT) was confirmed lends itself to testing of methods of prophylaxis. Similar animal experiments could end the present exclusive reliance on statistical analysis of data from large patient cohorts to evaluate prophylactic regimes. The reduction of need for such (usually retrospective) analyses could enable rationally-based clinical trials of prophylactic methods to be conducted more rapidly, and the success of such trials would lead to decreased incidences of DVT-related mortality and morbidity. This paper reviews the VCH hypothesis (\"VCH thesis\", following its corroboration) and its implications for understanding DVT and its sequelae, and outlines the experimental protocol for testing prophylactic methods. The advantages and limitations of the protocol are briefly discussed.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"156397"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30602099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombotic events associated to aspirin therapy. 与阿司匹林治疗相关的血栓事件。
Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-24 DOI: 10.1155/2012/247363
Christian Doutremepuich, Omar Aguejouf, Vanessa Desplat, Dominique Duprat, Francisco X Eizayaga
{"title":"Thrombotic events associated to aspirin therapy.","authors":"Christian Doutremepuich,&nbsp;Omar Aguejouf,&nbsp;Vanessa Desplat,&nbsp;Dominique Duprat,&nbsp;Francisco X Eizayaga","doi":"10.1155/2012/247363","DOIUrl":"https://doi.org/10.1155/2012/247363","url":null,"abstract":"<p><p>Acetyl salicylic acid (ASA) is widely used in clinical practice. Previous studies done in rats showed unexpected thrombotic potencies of this drug used at ultra-low doses. This review is the first report in which the effects of a wide range of ASA concentration on a microvessel model of laser-induced thrombus formation and Induced Hemorrhagic Time in animals were largely studied.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"247363"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/247363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30346872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. 心房颤动和冠状动脉疾病患者的抗凝血剂和抗血小板疗法。
Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-04-23 DOI: 10.1155/2012/184573
Karl Mischke, Christian Knackstedt, Nikolaus Marx
{"title":"Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.","authors":"Karl Mischke, Christian Knackstedt, Nikolaus Marx","doi":"10.1155/2012/184573","DOIUrl":"10.1155/2012/184573","url":null,"abstract":"<p><p>Anticoagulation represents the mainstay of therapy for most patients with atrial fibrillation. Patients on oral anticoagulation often require concomitant antiplatelet therapy, mostly because of coronary artery disease. After coronary stent implantation, dual antiplatelet therapy is necessary. However, the combination of oral anticoagulation and antiplatelet therapy increases the bleeding risk. Risk scores such as the CHA(2)DS(2)-Vasc score and the HAS-BLED score help to identify both bleeding and stroke risk in individual patients. The guidelines of the European Society of Cardiology provide a rather detailed recommendation for patients on oral anticoagulation after coronary stent implantation. However, robust evidence is lacking for some of the recommendations, and especially for new oral anticoagulants and new antiplatelets few or no data are available. This review addresses some of the critical points of the guidelines and discusses potential advantages of new anticoagulants in patients with atrial fibrillation after stent implantation.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"184573"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30610560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. 阿司匹林预防血栓形成：期望与局限。
Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-02-07 DOI: 10.1155/2012/104707
Gundu H R Rao, Jawad Fareed
{"title":"Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations.","authors":"Gundu H R Rao, Jawad Fareed","doi":"10.1155/2012/104707","DOIUrl":"10.1155/2012/104707","url":null,"abstract":"<p><p>Platelets play a very important role in the pathogenesis of acute vascular events leading to thrombosis of the coronary and cerebral arteries. Blockage of these arteries leading to regional ischemia of heart and brain tissues precipitate heart attacks and stroke. Acetyl salicylic acid (Aspirin) has been the drug of choice for over half a century for the primary and secondary prophylaxis of thrombotic events. In spite of its extensive use as an antiplatelet drug for the prevention of vascular thrombosis, there is considerable concern about the degree of protection it offers, to patients under aspirin therapy. In this paper, we explain the phenomenon of aspirin resistance, discuss the limitations of aspirin therapy, and suggest methods to monitor \"at-risk\" individuals. Ability to monitor and determine at risk patients will provide opportunities for the clinicians to customize antiplatelet therapies.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"104707"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30529056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. 低分子肝素在癌症患者中的临床应用:关注患者预后的改善。
Thrombosis Pub Date : 2011-01-01 Epub Date: 2011-04-12 DOI: 10.1155/2011/530183
Bo H Chao, Lisa Lepeak, Ticiana Leal, H Ian Robins
{"title":"Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.","authors":"Bo H Chao,&nbsp;Lisa Lepeak,&nbsp;Ticiana Leal,&nbsp;H Ian Robins","doi":"10.1155/2011/530183","DOIUrl":"https://doi.org/10.1155/2011/530183","url":null,"abstract":"<p><p>Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH) approximately two decades ago (in contrast to unfractionated heparin and vitamin K antagonists) has provided a class of agents with a favorable therapeutic index. In the review to follow, the literature regarding the use of LMWH in oncologic patient populations is summarized. Topics addressed include prophylaxis, and treatment as well as consideration of the potential anti-neoplastic properties of this class of drugs.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"530183"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/530183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. 血小板增多症:诊断评估，血栓风险分层，以及基于风险的管理策略。
Thrombosis Pub Date : 2011-01-01 Epub Date: 2011-06-08 DOI: 10.1155/2011/536062
Jonathan S Bleeker, William J Hogan
{"title":"Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.","authors":"Jonathan S Bleeker,&nbsp;William J Hogan","doi":"10.1155/2011/536062","DOIUrl":"https://doi.org/10.1155/2011/536062","url":null,"abstract":"<p><p>Thrombocytosis is a commonly encountered clinical scenario, with a large proportion of cases discovered incidentally. The differential diagnosis for thrombocytosis is broad and the diagnostic process can be challenging. Thrombocytosis can be spurious, attributed to a reactive process or due to clonal disorder. This distinction is important as it carries implications for evaluation, prognosis, and treatment. Clonal thrombocytosis associated with the myeloproliferative neoplasms, especially essential thrombocythemia and polycythemia vera, carries a unique prognostic profile, with a markedly increased risk of thrombosis. This risk is the driving factor behind treatment strategies in these disorders. Clinical trials utilizing targeted therapies in thrombocytosis are ongoing with new therapeutic targets waiting to be explored. This paper will outline the mechanisms underlying thrombocytosis, the diagnostic evaluation of thrombocytosis, complications of thrombocytosis with a special focus on thrombotic risk as well as treatment options for clonal processes leading to thrombocytosis, including essential thrombocythemia and polycythemia vera.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"536062"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/536062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 105
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. CYTO-PV:一项大规模试验，测试细胞减少治疗强度以预防真性红细胞增多症患者心血管事件。
Thrombosis Pub Date : 2011-01-01 Epub Date: 2011-05-17 DOI: 10.1155/2011/794240
Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Arianna Masciulli, Maria Rosaria Mennitto, Tiziano Barbui
{"title":"The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.","authors":"Roberto Marchioli,&nbsp;Guido Finazzi,&nbsp;Giorgina Specchia,&nbsp;Arianna Masciulli,&nbsp;Maria Rosaria Mennitto,&nbsp;Tiziano Barbui","doi":"10.1155/2011/794240","DOIUrl":"https://doi.org/10.1155/2011/794240","url":null,"abstract":"<p><p>Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events. Current guidelines advise maintaining hematocrit (HCT) level below 45% in males and 42% in females. Such targets lean on pathophysiological reasoning, while evidence from ECLAP and PVSG-01, the two largest prospective studies in this disease, suggests no difference in the rate of thrombosis in patients maintained at different HCT values below 50%-52%. Cytoreductive therapy in PV (CYTO-PV) is a multicenter, randomized, and controlled trial assess the benefit/risk profile of cytoreductive therapy with phlebotomy or HU aimed at maintaining HCT < 45% versus maintaining HCT in the range 45%-50%. CYTO-PV is being conducted in the framework of the Gruppo Italiano Malattie Ematologiche nell'Adulto (GIMEMA) and is funded by the Italian Drug Agency (AIFA). It is an independent trial with broad recruitment criteria to mimic clinical practice. We describe here the study and its advancement status. Conclusions. Clinical research in rare disease can be carried out with limited funds, provided a research hypothesis is felt as clinically relevant by a scientific community willing to share knowledge on the outcome of clinical practice, thus producing scientific results useful to improve treatment and prognosis of patients.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"794240"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/794240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 54
Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement. 尿液凝血酶原片段 1+2 与全膝关节置换术后发生非症状性和症状性静脉血栓栓塞事件的关系。
Thrombosis Pub Date : 2011-01-01 Epub Date: 2011-05-03 DOI: 10.1155/2011/150750
Lars C Borris, Morten Breindahl, Michael R Lassen, Akos F Pap
{"title":"Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement.","authors":"Lars C Borris, Morten Breindahl, Michael R Lassen, Akos F Pap","doi":"10.1155/2011/150750","DOIUrl":"10.1155/2011/150750","url":null,"abstract":"<p><p>Prothrombin fragment 1+2 is excreted in urine (uF1+2) as a result of in vivo thrombin generation and can be a marker of coagulation status after an operative procedure. This study compared uF1+2 levels in patients with symptomatic and non-symptomatic venous thromboembolism (VTE) after total knee replacement (TKR) and in event-free sex- and age-matched controls. Significantly higher median uF1+2 levels were seen in the VTE patients on days 1, 3, and the day of venography (mostly day 7) after TKR compared with controls. The uF1+2 levels tended to be high in some patients with symptomatic VTE; however, the discriminatory efficacy of the test could not be evaluated. In conclusion, this study showed that patients with VTE tend to have significantly higher uF1+2 levels compared with patients without events between days 1 and 7 after TKR surgery. Measurement of uF1+2 could provide a simple, non-invasive clinical test to identify patients at risk of VTE.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"150750"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30254944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Deep Vein Thrombosis with Continuous IV Infusion of LMWH: A Retrospective Study in 32 Children. 持续静脉滴注低分子肝素治疗32例儿童深静脉血栓的回顾性研究
Thrombosis Pub Date : 2011-01-01 Epub Date: 2011-04-14 DOI: 10.1155/2011/981497
Veronika Fiamoli, Jan Blatny, Ondrej Zapletal, Svetlana Kohlerova, Eva Janousova
{"title":"Treatment of Deep Vein Thrombosis with Continuous IV Infusion of LMWH: A Retrospective Study in 32 Children.","authors":"Veronika Fiamoli,&nbsp;Jan Blatny,&nbsp;Ondrej Zapletal,&nbsp;Svetlana Kohlerova,&nbsp;Eva Janousova","doi":"10.1155/2011/981497","DOIUrl":"https://doi.org/10.1155/2011/981497","url":null,"abstract":"<p><p>Thirty-two consecutive children aged 0-18 years with VTE treated with LMWH administered as a continuous infusion (CI) were identified at the Children's University Hospital Brno. The treatment led to at least partial resolution of the thrombus within two weeks in 85% of patients. There were no adverse events or increased bleeding reported in any patients. No recurrences were observed during a followup period of 6 months. Although continuous infusion should not replace subcutaneous (SC) administration of LMWH, CI appeared to be safe and efficient and may provide an alternate method of administering LMWH in a subset of the paediatric population where SC administration may not be feasible. Further prospective studies are needed to support the promising findings of our pilot clinical observation.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"981497"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30255361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信